FY2027 EPS Estimates for Insulet Lifted by Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Equities research analysts at Leerink Partnrs upped their FY2027 earnings per share (EPS) estimates for Insulet in a note issued to investors on Thursday, May 8th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will earn $7.10 per share for the year, up from their previous estimate of $6.89. The consensus estimate for Insulet’s current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet’s FY2028 earnings at $8.86 EPS and FY2029 earnings at $10.58 EPS.

Several other research analysts have also recently issued reports on PODD. Oppenheimer upped their price target on Insulet from $312.00 to $324.00 and gave the company an “outperform” rating in a report on Friday. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Stifel Nicolaus lifted their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Wells Fargo & Company set a $322.00 target price on Insulet in a report on Monday, April 28th. Finally, Canaccord Genuity Group raised their target price on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $303.81.

Insulet Price Performance

NASDAQ PODD opened at $310.42 on Monday. The stock has a market capitalization of $21.84 billion, a P/E ratio of 53.61, a P/E/G ratio of 3.62 and a beta of 1.26. Insulet has a 1 year low of $160.19 and a 1 year high of $312.80. The business’s fifty day moving average is $257.45 and its two-hundred day moving average is $263.88. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to analysts’ expectations of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm’s revenue was up 28.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 earnings per share.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at approximately $888,525. This represents a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.47% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Insulet

A number of hedge funds have recently modified their holdings of the stock. Larson Financial Group LLC boosted its holdings in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 81 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in Insulet in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. bought a new stake in Insulet in the fourth quarter worth $42,000. SRS Capital Advisors Inc. boosted its holdings in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 56 shares in the last quarter. Finally, Ramirez Asset Management Inc. bought a new stake in Insulet in the first quarter worth $53,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.